The addition of glucagon receptor agonism is particularly notable: preclinical evidence and early human data suggest it may increase energy expenditure and promote fat breakdown (lipolysis), potentially offering greater weight reduction than dual agonists alone though the precise contribution of each receptor in humans remains an active area of research
When to stop or reconsider GLP-1 therapy Not every Hashimoto's patient should stay on GLP-1 medications indefinitely
But by fixing the metabolic environment that makes migraines more likely, it may accomplish what no targeted migraine therapy has achieved: addressing the root cause rather than the symptom
Pharmacists play a critical role in educating patients on the appropriate and safe use of GLP-1 agonists and also bear responsibility in reporting suspected serious adverse events with this new class of antidiabetic agents
However, participants were only followed for 12 weeks in both studies
Villanueva-Pecarrillo ML, Mrquez L, Gonzlez N, et al